IP Library Granted Patent US 8,388,953
Granted Patent B2
US 8,388,953 · App. 12/826,403 · Granted Mar 5, 2013

Method of increasing cathepsin B-induced cleavage of amyloid-β peptides

Inventors: Li Gan (Burlingame, CA); Lennart Mucke (San Francisco, CA); Erik Roberson (Vestavia Hills, AL); Sarah Mueller-Steiner (Uitikon Waldegg, CH)
Assignee: The J. David Gladstone Institutes
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,388,953
App. No.
12/826,403
Granted
Mar 5, 2013
Kind
B2
Abstract

The present invention provides a method of increasing cathepsin B-induced cleavage of amyloid-β (Aβ) peptide in a cell or tissue, the method generally involving contacting the cell or tissue with an agent that increases the level of cathepsin B in the cell or tissue. The present invention further provides variant cathepsin B polypeptides that are resistant to inhibition by a cysteine protease inhibitor; as well as nucleic acids encoding the variants, and host cells comprising the nucleic acids.

Claims (11)

1. A method of increasing cathepsin B-induced cleavage of amyloid-β (Aβ) peptide in a neuron or a glial cell, the method comprising contacting the neuron or the glial cell with an agent that increases the level of cathepsin B-induced cleavage of Aβ in the neuron or the glial cell, wherein the agent is a non-steroidal anti-inflammatory agent.

2. The method of claim 1 , wherein the cell is a neuron.

3. The method of claim 1 , wherein the cell is a glial cell.

4. The method of claim 1 , wherein the agent is indomethacin.

5. The method of claim 1 , wherein the agent is ibuprofen.

6. The method of claim 1 , wherein the agent is acetylsalicylic acid, sulindac, glucametacine, acemetacin, Nalfon, Naproxen, piroxicam, diclofenac, benoxaprofen, ketoprofen, oxaprozin, etodolac, ketorolac, or nabumetone.

7. The method of claim 1 , wherein the Aβ is Aβ 1-42 .

8. The method of claim 1 , wherein the cathepsin B catalyzes carboxyl-terminal truncation of Aβ 1-42 .

9. The method of claim 1 , wherein the Aβ is cleaved at Va 1 40 -Ile 41 , Gly 38 -Gly 39 , or Gly 33 -Leu 34 .

10. The method of claim 1 , wherein the cathepsin B generates Aβ 1-40 , Aβ 1-38 , and Aβ 1-33 .

11. A method of increasing cathepsin B-induced cleavage of amyloid-β (Aβ) peptide in a neuron or a glial cell, the method comprising contacting the neuron or the glial cell with an agent that increases the level of cathepsin B-induced cleavage of Aβ in the neuron or the glial cell, wherein the agent is a non-steroidal anti-inflammatory agent selected from ibuprofen, indomethacin, acetylsalicylic acid, sulindac, glucametacine, acemetacin, Nalfon, Naproxen, piroxicam, diclofenac, benoxaprofen, ketoprofen, oxaprozin, etodolac, ketorolac, or nabumetone.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2010
From: GAN, LI; MUCKE, LENNART; ROBERSON, ERIK; MUELLER-STEINER, SARAH
To: THE J. DAVID GLADSTONE INSTITUTES
Reel/Frame 025244/0786 →
CONFIRMATORY LICENSE Recorded Jul 16, 2010
From: J. DAVID GLADSTONE INSTITUTES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024695/0260 →
Continuity (3)
Continuation 11985601 · Nov 15, 2007
Provisional Application 60859380 · Nov 15, 2006
Related Publication 20110256120A1 · Oct 20, 2011